The diagnosis and treatment of patients with brain tumors represents a particular challenge. Multiple disciplines of modern medicine are involved in both the diagnosis, e.g. neuropathology, neuroradiology, nuclear medicine, and the treatment, e.g. neurosurgery, radiation-oncology, neurology, medical oncology, of brain tumors. Neurooncology is thus a very interdisciplinary area of oncology and requires the excellent cooperation of multiple disciplines. Since early 2012 the activities at the University Hospital Zurich in the area of neurooncology are coordinated by the newly founded
Brain Tumor Center at the Cancer Center Zurich. The principles of diagnosis and management are summarized in German here:
Empfehlungen zur Diagnostik, Therapie und Nachsorge.
Diagnosis and treatment of brain tumors are a major focus of the Department of Neurology at the University Hospital in Zurich. We offer continuous counseling, treatment and follow-up of patients and their relatives from the Canton of Zurich as well as further Cantons of Switzerland as well as a counseling and treatment service for patients from foreign countries who visit Zurich only occasionally in larger intervals. The outpatient clinic is open Monday through Friday.
The interdisciplinary tumorboard takes place on Monday at 8.30. Brain tumor patients of the University Hospital Zurich as well from external institutions are discussed with their medical history. The corresponding pathology and imaging data are presented. We develop interdisciplinary recommendations for diagnosis and treatment which are accordingly documented. There is the opportunity for external colleagues to submit their patient cases with specific questions to our boards and present them either personally or through our team. Contacts for the interdisciplinary tumor boards are PD Dr. Patrick Roth (firstname.lastname@example.org), Dr. Caroline Hertler (email@example.com) and Dr. Dorothee Gramatzki (firstname.lastname@example.org, +41 44 255 48 21).
The enrolment of patients into clinical trials pursues the goal of further improving the standards of care for brain tumor patients. The initiation and coordination of clinical trials in Zurich is done in close cooperation of our department and the partner institutions at the Brain Tumor Center Zurich with clinical trial consortia such as the EORTC (European Organization for Research and Treatment of Cancer) as well as the pharmaceutical industry. Currently we offer participation in clinical trials for patients with newly diagnosed and recurrent
glioblastoma as well as for patients with
meningioma. Contacts for our ongoing clinical trials are indicated
Patients with newly diagnosed glioblastoma and a methylated MGMT promotor can participate in the randomized phase II trial evaluating nivolumab or placebo in addition to temozolomide-based radiochemotherapy (CheckMate 548). The phase III trial
CheckMate 498 comparing the addition of anti-PD-1 (Programmed Death Receptor 1) antibody nivolumab to radiotherapy with temozolomide-based radiochemotherapy for patients with newly diagnosed glioblastoma with an unmethylated MGMT promotor was recently completed. For patients with newly diagnosed glioblastoma and an amplification of the epidermal growth factor receptor (EGFR) gene, the phase IIb/III trial
M13-813 evaluate the EGFR-targeted antibody drug conjugate ABT-414 or placebo added to temozolomide-based radiochemotherapy. The phase III trial
STING for patients with newly diagnosed glioblastoma randomizes patients to either radiochemotherapy with temozolomide plus the ICT-107 vaccine (autologous dendritic cells pulsed with six tumor antigens MAGE1, HER-2, AIM-2, TRP-2, gp100 und IL13Ralpha2) or radiochemotherapy with temozolomide plus placebo. Another clinical trial for patients with newly diagnosed glioblastoma, the MRZ-112 trial, is a phase Ib, multicenter, open-label study evaluating the proteasome inhibitor marizomib combined with radiotherapy and temozolomide.
For patients with recurrent glioblastoma, we offer participation in the
PQR309-004 trial, an open-label, non-randomized, two-stage study to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamic effects of PQR309 in patients with first progression of glioblastoma. The recruitment of patients for this trial is currently on hold.
For patients with recurrent meningioma of WHO grades II or III and no option of surgery or radiotherapy, we can offer participation in the multicenter randomized phase II study
EORTC 1320. This trial evaluates trabectedin versus local standard of care therapy. Patients with meningioma of all WHO grades can participate in an observational study evaluating neurocognitive function and quality of life after surgery or radiotherapy.
Primary CNS lymphoma
Patients with recurrent primary CNS lymphoma can participate in the phase II trial
PQR309-005, an open-label, non-randomized, study evaluating the efficacy and safety of the PQR309.
Donations for our scientific work (details here
) can be made via bank transfer to either of the following accounts:
Transfer to our postal giro account: Recipient: Rechnungswesen der Universität Zürich 8001 Zürich, giro account no.: 80-643-0, IBAN: CH46 0900 0000 8000 0643 0, BIC: POFICHBEXXX
Transfer to our bank account: Recipient: Universität Zürich CH-8001 Zürich, account no. 1100-0109.594(BC 700) - Zürcher Kantonalbank, CH-8010 Zürich, Swift-Code: ZKBKCHZZ80A, IBAN: CH51 0070 0110 0001 0959 4
For accounting purposes we would like to ask you to add the "payable to" notice as follows: "Zu Gunsten des Kontos F-86001-01-01". If you want to choose the intended purpose in detail, please contact us before or after your bank transfer (tel. +41 44 255 55 00). We will be pleased to send you an official confirmation of your donation by simply contacting us via our telephone number +41 44 255 55 00.
5th Meeting of the "World Federation of Neuro-Oncology Societies" takes place in Zurich (Kongresshaus) in May 3-7, 2017.
Prof. Dr. M. Weller
University Hospital Zurich
Department of Neurology